UNION THERAPEUTICS AS

Their core work

Union Therapeutics (operating under the project name AntibioTx) is a Danish biotech SME focused on discovering and developing novel antibiotic compounds, with a specific clinical focus on skin infections in inflammatory conditions such as atopic dermatitis. Their lead asset ATx201 represents a proprietary antibiotic class aimed at filling a genuine therapeutic gap where standard antibiotics underperform. Beyond their own pipeline, they have partnered in EU-funded academic training networks dedicated to advancing the next generation of antibiotics by targeting bacterial functional mechanisms rather than conventional pathways. They operate as a small, science-driven company bridging early drug discovery and commercial translation.

What they specialise in

How they've shifted over time

With only two projects spanning 2016–2017 and no keyword data available, evolution is limited but still telling. In 2016, the company focused on applied commercial validation — using the SME Instrument to assess a specific antibiotic compound (ATx201) for a defined dermatology indication. By 2017, they shifted toward broader academic collaboration, joining a Marie Curie training network (Train2Target) pursuing next-generation antibiotic mechanisms across a large international consortium. This suggests a deliberate dual-track strategy: advancing their own pipeline commercially while deepening scientific credibility through research partnerships.

They appear to be building scientific depth alongside commercial pipeline work — a pattern typical of biotech SMEs preparing for licensing deals or clinical partnerships, making them a plausible partner for academic-industry consortia in the AMR space.

How they like to work

They have served both as project coordinator (ATx201, solo SME Instrument) and as a consortium participant (Train2Target, a large MSCA training network with 16 partners across 8 countries). Their coordinator experience is limited to a small feasibility grant, while their network participation suggests they can integrate into complex multi-partner academic structures. Working with them likely means engaging a small, focused team that brings industrial drug-development perspective into research-heavy consortia.

Their combined H2020 activity generated 16 unique consortium partners across 8 countries, almost entirely through the Train2Target MSCA network — a large distributed training consortium typical of ITN grants. Their direct partnership network outside that context appears limited given their size and stage as an SME.

What sets them apart

AntibioTx/Union Therapeutics occupies a specific niche within European biotech: a small Danish company with a proprietary antibiotic compound targeting dermatological infections — an underserved clinical area within the broader AMR field. Unlike most AMR-focused SMEs that target systemic or hospital-acquired infections, their focus on skin conditions (atopic dermatitis) gives them a more defined regulatory and commercial pathway. For consortia needing an industry partner with both a real drug pipeline and AMR research credentials, they offer a credible if early-stage option.

Highlights from their portfolio

• Train2Target
  As a participant in this large MSCA Innovative Training Network (EUR 290,082 received), they contributed industrial drug-development expertise to a pan-European PhD training program on next-generation antibiotic targets — demonstrating academic-industry bridge capability.
• ATx201
  As coordinator of an SME Instrument Phase 1 grant, they validated a proprietary antibiotic compound for infected atopic dermatitis — a rare example of an EU-funded feasibility study for a dermatology-specific antibiotic.